Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma
2024; Ivyspring International Publisher; Volume: 14; Issue: 9 Linguagem: Inglês
10.7150/thno.96944
ISSN1838-7640
AutoresSimone C. Kleinendorst, Egbert Oosterwijk, Janneke D.M. Molkenboer‐Kuenen, Cathelijne Frielink, Gerben M Franssen, Daan F Boreel, Giulia Tamborino, Manon Gloudemans, M. Hendrikx, Dennis Kroon, Jopp Hillen, Johan Bussink, Stijn Muselaers, Peter Mulders, Mark W Konijnenberg, Michael P Wheatcroft, Kwame Twumasi‐Boateng, Sandra Heskamp,
Tópico(s)Microtubule and mitosis dynamics
ResumoImmune checkpoint inhibitors (ICI) are routinely used in advanced clear cell renal cell carcinoma (ccRCC). However, a substantial group of patients does not respond to ICI therapy. Radiation is a promising approach to increase ICI response rates since it can generate anti-tumor immunity. Targeted radionuclide therapy (TRT) is a systemic radiation treatment, ideally suited for precision irradiation of metastasized cancer. Therefore, the aim of this study is to explore the potential of combined TRT, targeting carbonic anhydrase IX (CAIX) which is overexpressed in ccRCC, using [
Referência(s)